Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005096 · ClinicalTrials.gov registry record · Phase 2
Docetaxel in Treating Patients With Stage II or Stage III Prostate Cancer
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT00005096 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 19 participants.
The verdict
NCT00005096, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of docetaxel in treating patients who have stage II or stage III prostate cancer.
Interventions
- DRUG docetaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 1999-12 |
| Est. Completion | 2002-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005096
The ClinicalTrials.gov registry entry for NCT00005096 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which docetaxel is the first listed.
NCT00005096 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005096 about?
NCT00005096 is a clinical study titled "Docetaxel in Treating Patients With Stage II or Stage III Prostate Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of docetaxel in treating patients who have stage II or stage III prostate cancer.
What is the current status of trial NCT00005096?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 1999-12. Estimated completion is 2002-06.
What interventions are being tested in trial NCT00005096?
The interventions under investigation include: docetaxel (DRUG).
Who is sponsoring clinical trial NCT00005096?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.